Clinical Trial

Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Trial Details
NCT Number NCT07033858
Lead Sponsor Shahid Beheshti University of Medical Sciences
Conditions Kidney Transplant; Complications
Enrollment 50 participants
Start Date 2025-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-24